{"product_id":"rush-university-medical-center-3rd-midwest-cellular-conference-treatment-options-for-advanced-hematologic-malignancies-2024","title":"Rush University Medical Center 3rd Midwest Cellular Conference Treatment Options for Advanced Hematologic Malignancies 2024","description":"\u003cdiv class=\"elementor-element elementor-element-3d496a51 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"3d496a51\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"elementor-widget-container\"\u003e\n\u003ch3\u003eRush University Medical Center 3rd Midwest Cellular Conference Treatment Options for Advanced Hematologic Malignancies 2024\u003c\/h3\u003e\n\u003cstrong\u003e Include: 16 videos, size: 4.5 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: hematologists, medical oncologists, pharmacists, fellows and residents\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"sqs-block html-block sqs-block-html\" data-block-type=\"2\" data-border-radii=\"{\" id=\"block-yui_3_17_2_1_1635964884278_2264\" topleft\u003e\n\u003cdiv class=\"sqs-block-content\"\u003e\n\u003cdiv class=\"sqs-html-content\"\u003e\n\u003cp class=\"\"\u003e\u003cspan class=\"sqsrte-text-color--darkAccent\"\u003eTreatment options for relapsed\/refractory (advanced) hematologic malignancies have progressed rapidly in only the last decade. Development of revolutionary treatment options, including CAR T-cell therapy, novel immunotherapies, and novel chemotherapeutic agents has only accelerated since the first product targeting CD19 was developed in 2003. These developments provide excellent opportunities for patients, and with opportunities arrive challenges for clinicians in maintaining optimal approaches to care. To address the educational need the 3rd Midwest Therapy Cellular Conference: Treatment Options for Advanced Hematologic Malignancies is planned .\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp class=\"p2\"\u003eThis program is designed to meet the educational needs of hematologists, medical oncologists, pharmacists, fellows and residents, APP’s, oncology nurses and other healthcare professionals committed to the field of cellular treatment options for advanced hematologic malignancies.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eLEARNING OBJECTIVES\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"\"\u003e\u003cspan class=\"sqsrte-text-color--darkAccent\"\u003eFollowing participation in this activity, learners will:\u003c\/span\u003e\u003c\/p\u003e\n\u003col data-rte-list=\"default\"\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cspan class=\"sqsrte-text-color--darkAccent\"\u003eDiscuss individualized treatment options for high-risk patients with plasma cell diseases (multiple myeloma (MM), amyloidosis), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL),non-Hodgkin Lymphoma (NHL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and aplastic anemia (AA).\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cspan class=\"sqsrte-text-color--darkAccent\"\u003eInclude autologous or allogeneic HCT and\/or CAR-T cell therapy in treatment plans for patients with various refractory (advanced) hematologic malignancies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cspan class=\"sqsrte-text-color--darkAccent\"\u003eManage potential complications resulting from autologous or allogeneic HCT and\/or CAR-T cell therapy.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cspan class=\"sqsrte-text-color--darkAccent\"\u003eUtilize newer chemotherapeutic treatment options in conjunction with HCT and CAR-T cell therapy for patients with various refractory (advanced) hematologic malignancies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAdvancements in Richter’s Transformation- Novel Agents and Cellular Therapies.mp4\u003c\/li\u003e\n\u003cli\u003eAllo-HSCT Conditioning Regimens- Current Status and Future Directions.mp4\u003c\/li\u003e\n\u003cli\u003eBCMA \u0026amp; Beyond- Novel Targets for Immunotherapy in MM.mp4\u003c\/li\u003e\n\u003cli\u003eBone Marrow Failure- The Importance of Mutational Testing.mp4\u003c\/li\u003e\n\u003cli\u003eCAR-T vs. Bispecific Antibodies in RR MM- Insights and Future Directions.mp4\u003c\/li\u003e\n\u003cli\u003eCellular Therapy Strategies for Persistent Disease After Induction for B-ALL.mp4\u003c\/li\u003e\n\u003cli\u003eChallenges and Treatment Strategies in Advanced Stage Hodgkin Lymphoma.mp4\u003c\/li\u003e\n\u003cli\u003eHigh-Risk Myeloma- Updates in Defining and Managing.mp4\u003c\/li\u003e\n\u003cli\u003eIs Post-HSCT Maintenance the SOC for AML..mp4\u003c\/li\u003e\n\u003cli\u003eManagement of Viral Infections Post-Transplant- CMV, EBV, and HHV-6.mp4\u003c\/li\u003e\n\u003cli\u003eOff the Shelf CARs for DLBCL- Myths and Facts.mp4\u003c\/li\u003e\n\u003cli\u003eOptimal Timing of CAR T-Cell Therapies in MCL- Cellular Therapy and Beyond.mp4\u003c\/li\u003e\n\u003cli\u003eSelection and Sequencing of Chronic GVHD Therapy.mp4\u003c\/li\u003e\n\u003cli\u003eThe Role of SCT Amidst Emerging Therapies in the Treatment of AL Amyloidosis.mp4\u003c\/li\u003e\n\u003cli\u003eTransplant-Associated TMA- Challenges and Current Treatment Options.mp4\u003c\/li\u003e\n\u003cli\u003eWhat is New in AML- Risk Classification, Germline Mutations, and Targeted Therapies.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954442080354,"sku":"MED-AMB03620","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Rush-University-Medical-Center-3rd-Midwest-Cellular-Conference-Treatment-Options-for-Advanced-Hematologic-Malignancies-2024.jpg?v=1779376848","url":"https:\/\/meducourse.com\/products\/rush-university-medical-center-3rd-midwest-cellular-conference-treatment-options-for-advanced-hematologic-malignancies-2024","provider":"Meducourse","version":"1.0","type":"link"}